Pfizer Unveils New End-To-End Digital Consumer Platform

PfizerForAll is a digital service designed to make getting medicines easier, and will be available to consumers for vaccines and migraine medicines. 

Pfizer is launching an end-to-end digital platform for some of its medicines and vaccines • Source: Shutterstock

Pfizer Inc. introduced the PfizerForAll platform with a goal of making some of its vaccines and medicines available to patients faster and more conveniently. The new digital platform, announced 27 August, is designed to make accessing medicines easier for consumers, starting with a few of the key disease areas Pfizer is involved in.

PfizerForAll will be available for patients with migraine, COVID-19 or flu and will be an option for patients seeking medicines for migraine or vaccines for COVID-19, respiratory syncytial virus (RSV) or pneumococcal pneumonia, the company said.

Pfizer markets the COVID-19 vaccine Comirnaty, the RSV vaccine Abrysvo, the pneumococcal vaccine Prevnar20 and the migraine medicines Nurtec ODT (rimegepant) and Zavzpret (zavegepant). However, the service won’t only provide Pfizer medicines and vaccines. “This isn’t just Pfizer’s treatments or vaccines. It is dependent on what the prescriber chooses for an individual,” the company told Scrip.

The timing of the launch coincides with the fall vaccination season and Pfizer hopes it will simplify the process for consumers.

“We once again face the threat of a possible tripledemic with influenza, RSV and COVID-19 co-circulating,” Pfizer told Scrip. “The growing number of approved vaccines, diagnostics and treatments to address respiratory illnesses is welcome news for society. However, this rapid pace of innovation has added complexity to the landscape for individuals, families and health care professionals.”

PfizerForAll works within the existing health care system, using a growing network of partners to simplify access.

Consumers can use their existing insurance and pharmacy programs on PfizerForAll, which is partnered with direct service companies UpScriptHealth, Alto Pharmacy and Instacart. The platform aims to solve some of the complexity in the US health care system and provide a new digital option for patients to manage their care.

PfizerForAll will provide access to same-day appointments with independent health care professionals, including both in-person and via telehealth, and it will provide home delivery of prescription medicines, over-the-counter treatments and diagnostic tests, or pick up at a preferred local pharmacy.

Another feature on the platform is scheduling for adult COVID-19, flu, RSV and pneumococcal pneumonia vaccinations. And, when it comes to paying for services or medications, PfizerForAll will have savings and support information in one place, with the goal of making it easier to find copay cards for eligible patients to access Pfizer’s support programs.

Pfizer is launching a multi-channel marketing campaign to make consumers and health care providers aware of the PfizerForAll platforms where they are most active.

“Our campaign is focused on reaching key audiences, including health care decision-makers who manage health and wellness decisions for themselves and their families, and those seeking support and looking to take key health actions related to our therapeutic areas of focus,” Pfizer said.

The company said it plans to expand and develop PfizerForAll, with the potential to address a broader range of needs and conditions.

More from Business

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

 
• By 

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

More from Scrip

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?